Presentations by Program

Search by Program

Pharmacokinetics/pharmacodynamics of the β-lactamase inhibitor, durlobactam, in combination with sulbactam against Acinetobacter baumannii-calcoaceticus Complex

John O'Donnell, Brian Van Scoy, Sujata Bhavnani, Paul Ambrose, Sarah McLeod and Ruben Tommasi (ASM Microbe, 2022)

In vitro activity of sulbactam-durlobactam in combination with other antimicrobial agents

Nicole Carter, Sarah McLeod, Adam Shapiro and Alita Miller (ASM Microbe, 2022)

Sulbactam-durlobactam is bactericidal against clinical isolates of Acinetobacter baumannii

Nicole Carter, Sarah McLeod, Adam Shapiro and Alita Miller (ASM Microbe, 2022)

ETX0462, a novel, non-β-lactam PBP inhibitor, has potent antibacterial activity against a panel of geographically diverse Gram-negative bacterial clinical isolates

John O'Donnell, Ramkumar Iyer, Thomas Durand-Reville, Ruben Tommasi, Stephen Hawser, Cyntia De Piano, Thomas Valmont, Ian Morrissey, Alita Miller (ASM Microbe, 2022)

ETX0462, a novel non-β-lactam PBP inhibitor, does not induce AmpC expression

Samir Moussa and Alita Miller (ASM Microbe, 2022)